Literature DB >> 9500961

Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats.

C V Borlongan1, Y Tajima, J Q Trojanowski, V M Lee, P R Sanberg.   

Abstract

This study was designed to explore the efficacy of a human clone cell line as an alternative neural graft source and to validate the practice of cryopreservation and xenografting as logistical approaches toward conducting neural transplantation. We investigated the biological effects of transplanting cultured human neurons (NT2N cells) derived from a well-characterized embryonal carcinoma cell line into the brains of rats subjected to transient, focal cerebral ischemia induced by embolic occlusion of the middle cerebral artery. At 1 month and extending throughout the 6-month posttransplantation test period, ischemic animals that were transplanted with NT2N cells and treated with an immunosuppressive drug displayed a significant improvement in a passive avoidance task as well as a normalization of asymmetrical motor behavior compared to ischemic animals that received rat fetal cerebellar cell grafts or vehicle alone. Remarkably, cryopreserved NT2N cell grafts compared with fresh NT2N cell grafts, remained viable in the immunosuppressed rat brain and effective in producing behavioral recovery in immunosuppressed ischemic animals. The long-term viability of cryopreserved NT2N cell xenografts in vivo and their sustained effectiveness in promoting behavioral recovery suggest potential utilization of xenografting and cryopreservation as useful protocols for establishing clone cell lines as graft source in neural transplantation therapies for central nervous system disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500961     DOI: 10.1006/exnr.1997.6730

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  75 in total

Review 1.  From teratocarcinomas to embryonic stem cells.

Authors:  Peter W Andrews
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

Review 2.  Cell therapy for stroke.

Authors:  Sean I Savitz; Jonathan H Dinsmore; Lawrence R Wechsler; Daniel M Rosenbaum; Louis R Caplan
Journal:  NeuroRx       Date:  2004-10

3.  In vivo Tracking of Transplanted Bone Marrow-Derived Mesenchymal Stem Cells in a Murine Model of Stroke by Bioluminescence Imaging.

Authors:  Kyung-Sool Jang; Kwan-Sung Lee; Seung-Ho Yang; Sin-Soo Jeun
Journal:  J Korean Neurosurg Soc       Date:  2010-11-30

4.  Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia.

Authors:  Piotr Walczak; Jian Zhang; Assaf A Gilad; Dorota A Kedziorek; Jesus Ruiz-Cabello; Randell G Young; Mark F Pittenger; Peter C M van Zijl; Judy Huang; Jeff W M Bulte
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914

5.  Intracranial delivery of stem cells.

Authors:  Keith W Muir; John Sinden; Erik Miljan; Laurence Dunn
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

Review 6.  Approaches for neural tissue regeneration.

Authors:  Loïc Binan; Abdellah Ajji; Gregory De Crescenzo; Mario Jolicoeur
Journal:  Stem Cell Rev Rep       Date:  2014-02       Impact factor: 5.739

7.  Injected Versus Oral Cyclosporine for Human Neural Progenitor Grafting in Rats.

Authors:  Matthew B Jensen; Rajeev Krishnaney-Davison; Laura K Cohen; Su-Chun Zhang
Journal:  J Stem Cell Res Ther       Date:  2012-04-20

8.  Cell therapy for ischaemic stroke.

Authors:  D C Hess; W D Hill
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

9.  THE CASE FOR AN ETHICS RESEARCH CONSORTIUM FOR EMERGING TECHNOLOGIES: PUBLIC PERCEPTION OF STEM CELL RESEARCH AND DEVELOPMENT.

Authors:  Cesar V Borlongan; Camille McWhirter; Caroline Fultz-Carver; Kevin T Fitzgerald; Paul R Sanberg
Journal:  Technol Innov       Date:  2010-01-01

10.  Hibernation-like state induced by an opioid peptide protects against experimental stroke.

Authors:  Cesar V Borlongan; Teruo Hayashi; Peter R Oeltgen; Tsung-Ping Su; Yun Wang
Journal:  BMC Biol       Date:  2009-06-17       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.